Video

Dr. McLaughlin on Lymphedema in Breast Cancer

Sara McLaughlin, MD, professor of Surgery, Mayo Clinic, discusses the frequency that lymphedema appears in patients with breast cancer and addresses the complications in identifying this after her presentation at the Lynn Sage Breast Cancer Symposium.

Sara McLaughlin, MD, professor of surgery, Mayo Clinic, discusses the frequency that lymphedema appears in patients with breast cancer, as well as addresses the complications in identifying the condition following her presentation at the 2018 Lynn Sage Breast Cancer Symposium.

McLaughlin says their estimations are that 5% of women with a sentinel node biopsy and 20% of women with an axillary node dissection experience lymphedema. This also increases when compound radiation is added to an axillary procedure. In these cases, the rates of lymphedema can nearly double, she explains.

According to McLaughlin, lymphedema may be more common than is currently known in the field. This is because lymphedema does not develop until 3 to 5 years following their treatment. Moreover, most studies do not follow patients this far out, meaning it can often go unreported.

View more from the 2018 Lynn Sage Breast Cancer Symposium

Related Videos
Sagar D. Sardesai, MBBS
DB-12
Albert Grinshpun, MD, MSc, head, Breast Oncology Service, Shaare Zedek Medical Center
Erica L. Mayer, MD, MPH, director, clinical research, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Stephanie Graff, MD, and Chandler Park, FACP
Mariya Rozenblit, MD, assistant professor, medicine (medical oncology), Yale School of Medicine
Maxwell Lloyd, MD, clinical fellow, medicine, Department of Medicine, Beth Israel Deaconess Medical Center
Neil Iyengar, MD, and Chandler Park, MD, FACP
Azka Ali, MD, medical oncologist, Cleveland Clinic Taussig Cancer Institute
Rena Callahan, MD, and Chandler Park, MD, FACP